Cat. No.: DAB-0011921
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro223 of human COX2/MT-CO2 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MT-CO2 |
| UniProt No. | P00403 |
| Gene ID | 4513 |
| Gene Description | The electron transport chain is a series of mitochondrial protein complexes that utilize coupled reduction-oxidation reactions to transfer electrons from donor molecules to acceptors. By coupling this electron transport with active proton pumping across the inner mitochondrial membrane, an electrochemical gradient is generated that is used to drive ATP synthesis. Complex IV is the terminal complex of the respiratory chain, responsible for transporting electrons from cytochrome c to molecular oxygen. COX2, also known as MT-CO2, is one of 14 subunits of cytochrome c oxidase, and one of three subunits encoded by the mitochondrial genome. These three mitochondrial-encoded subunits form the functional core of cytochrome c oxidase. Research studies have shown that disruptions to COX2/MT-CO2 function can have deleterious health effects. For example, a novel point mutation in the COX2/MT-CO2 gene was identified as a risk factor for cardiovascular disease, whereas a separate point mutation was causally linked to adult onset cerebellar ataxia. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
